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Abstract
A case of leptomeningeal carcinomatosis in a patient with known brain and lung metastases from renal cell cancer 
without previous systemic therapy is presented. Neoplastic meningitis (NM) developed 31 months after first diagnosis 
of simultaneous extra- and intracranial recurrence of kidney cancer and surgical resection of a cerebellar metastasis. In 
spite of local radiotherapy to the macroscopic NM lesions in the cervical and lumbar spine followed by initiation of 
sunitinib, the patient succumbed to his disease 4 months after the diagnosis of NM. The untreated lung metastases 
progressed very slowly during almost 3 years of observation. This case illustrates important issues around both 
biological behaviour and treatment approaches in metastatic renal cell cancer.
Background
Brain metastases from renal cell carcinoma might
develop many years after primary nephrectomy and con-
tinue to represent a formidable challenge [1]. With
increasing numbers of local and systemic treatment
options, the issue of patient selection gains importance.
While surgery and stereotactic radiosurgery (SRS) pro-
vide long-term local control of macroscopic disease,
development of new central nervous system lesions can
often be observed. Some patients might even present
with leptomeningeal carcinomatosis or so called neoplas-
tic meningitis (NM). Only few cases of NM from renal
cell carcinoma treated with contemporary systemic
approaches have been reported [2,3]. Therefore, the pres-
ent case illustrates important aspects around potential
treatment options.
Case presentation
A 72-year-old male presented to his family doctor with a
3 week history of headache and dizziness. His medical
history was unremarkable except for left-sided nephrec-
tomy for clear cell renal cell cancer stage T2 N0 M0 8
years earlier. Diagnostic imaging with brain computed
tomography (CT) scan followed by magnetic resonance
imaging (MRI) revealed a 3 cm large contrast-enhancing
infratentorial tumor (Figure 1). No additional brain
lesions were detected. CT of chest and abdomen revealed
2 small lung nodules (one left-sided, one right-sided) and
enlarged mediastinal lymph nodes (Figure 2). Neurosur-
gical resection of the intracranial tumor confirmed
metastasis from clear cell carcinoma. Neither postopera-
tive radiotherapy nor systemic treatment was recom-
mended at this time. Surveillance CT scans showed very
slow enlargement of the lung and lymph node metastases
during the next year. Seventeen months after resection of
the cerebellar metastasis, local recurrence was detected.
The patient was treated with gamma knife SRS (periph-
eral dose 21 Gy). Six months later, a single new brain
metastasis was found (8 mm large, left occipital lobe),
which also was treated with SRS. Seven months after the
second SRS procedure, a third one was added after diag-
nosis of two new infratentorial brain lesions (cerebellum
and brain stem, respectively). Treatment planning MRI
also revealed a contrast-enhancing extramedullary mass
at the level of the 5th cervical vertebra. Additional scans
of the spine showed at least two more small metastases in
the lower thoracic and upper lumbar region (Figure 3).
No cerebrospinal fluid (CSF) examination was performed
as imaging and history were consistent with a diagnosis of
NM. The involved regions were treated with fractionated
external beam radiotherapy (10 fractions of 3.5 Gy). At
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Page 2 of 4that time, the patient had a Karnofsky performance status
(KPS) of 70. He had no new focal neurologic deficits, but
continued to experience dizziness and gait disturbance
since his first SRS procedure. Because of intense pain in
different skeletal regions, a radioisotope bone scan was
performed, which showed bone metastases in the corre-
sponding areas. These metastases were confirmed by
radiographs and/or CT. Analgetic treatment with opiods
was started and external beam radiotherapy fields were
added to parts of the pelvis, femur and shoulder. For the
first time during follow-up, elevated lactate dehydroge-
nase levels (266 U/L) and lymphopenia (0.3 × 109/L) were
seen. The known lung and lymph node lesions continued
to progress slowly (Figure 2). Three weeks after radio-
therapy, the first systemic treatment was initiated, con-
sisting of sunitinib 50 mg per day. After two weeks on
sunitinib, the patient presented to the emergency room
with chills and reduced general condition. Fever (38.7°C),
elevated C-reactive protein (CRP) level (235 mg/L), leu-
kopenia (3.2 × 109/L) and thrombopenia (73 × 109/L)
were found. Blood- and urine cultures were negative.
Chest X-ray showed a small infiltrate. Sunitinib treatment
was stopped and antibiotic therapy initiated. The patient
recovered, but was still unable to reduce analgesics and
had a KPS of 50. The treating oncologists decided to stop
active cancer treatment. Three weeks later, he began to
lose strength in the lower extremities. Steroid treatment
was unsuccessful. Imaging was not repeated as manage-
ment would not have been altered. Another three weeks
later, the patient again presented to the emergency room
with chest pain, dyspnea and tachycardia. Chest X-ray
revealed pneumonia, CRP was elevated to 228 mg/L, leu-
kocyte counts normal (6.6 × 109/L). In spite of antibiotic
treatment, the patient succumbed to his disease a few
hours after admission. Survival was 11 years from neph-
rectomy, 35 months from initial diagnosis of brain and
lung metastases, and 4 months from NM and bone
metastases.
Conclusions
NM from renal cell carcinoma is a rare event, with only
few cases reported to date [2,3]. In the present patient, it
was preceded by brain metastases, initially a single cere-
bellar lesion, which was surgically removed. Whether
resection of posterior fossa metastases increases the risk
of leptomeningeal dissemination is a topic of debate.
Recent data suggest that en bloc removal of metastatic
lesions does not increase the risk [4]. Fractionated exter-
nal beam radiotherapy might offer symptom palliation in
Figure 1 Preoperative T1-weighted magnetic resonance imaging 
showing a 3 cm large contrast-enhancing infratentorial tumor.
Figure 2 Computed tomography of the chest showing mediasti-
nal lymph node enlargement (upper image: September 2005, i.e. 
initial diagnosis of metastases). Slow progression in the absence of 
treatment (lower image: June 2008, i.e. before initiation of sunitinib 
therapy). The white arrow indicates metastasis in a thoracic vertebra.
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Median survival was 3 months. Median survival and
long-term survival rates are higher in patients treated
with surgical resection or SRS. In a series of 32 patients,
SRS resulted in median survival of 10 months and 3-year
survival of 16% [6]. A large analysis including more than
1000 patients treated with SRS without additional whole-
brain radiotherapy (WBRT) showed that approximately
50% developed new lesions (several types of primary
tumors were included) [7]. Comparable findings were
made in surgery series. The addition of WBRT to either
SRS or surgical resection decreased the in-brain failure
rates but failed to improve survival, most likely because
new lesions can be treated with salvage SRS or surgery [8-
10]. It has been argued that delaying WBRT may be
appropriate for some subgroups of patients with SRS-
treated brain metastases from renal cell carcinoma and
other relatively radioresistant tumors [11]. As these sub-
groups are not well defined, individual discussion and
decision is necessary. In the present case, no postopera-
tive radiotherapy was administered. Instead, salvage SRS
was given to the sites of intracranial relapse. A previous
study included analyses of the impact of systemic treat-
ment on survival. Systemic immunotherapy with inter-
leukin-2 and interferon was associated with improved 3-
year survival, while treatment with antiangiogenic agents
was not [6]. Nevertheless, antiangiogenic agents have
become a mainstay of treatment in the general population
of patients with metastatic renal cell carcinoma and occa-
sional responses of brain metastases to these drugs have
been reported [12]. In another series with 138 renal cell
carcinoma patients with brain metastases, 5-year survival
was 12% [13], suggesting that aggressive management
should be considered in prognostically favorable patients.
Surgical resection should be considered in patients with
renal cell carcinoma developing metachronous lung
metastases [14], but in the present case bilateral lesions
and mediastinal lymph node metastases were detected. In
addition, the diagnosis of brain metastasis argued against
lung surgery. The untreated lung and lymph node lesions
progressed very slowly (Figure 2), a finding not uncom-
mon in this disease. Nevertheless, these metastases might
have been the source of further dissemination. The slow
growth rate and absence of clinical symptoms prompted
the treating oncologists to postpone systemic therapy.
This decision was also influenced by the potential serious
toxicity of systemic therapy. If tailored to the clinical
symptoms, systemic therapy would not have been neces-
sary before the almost simultaneous detection of leptom-
eningeal and bone metastases. However, at that time
careful consideration of treatment options was necessary.
It was felt that radiotherapy to the macroscopic spinal
lesions was more appropriate than to the complete cran-
iospinal axis, both with regard to reduced bone marrow
toxicity and treatment time. The aim was to avoid delays
in systemic therapy or reduced doses because of neutro-
and/or thrombopenia. Intrathecal chemotherapy should
be considered in patients with NM from breast cancer or
hematologic malignancies. In patients with renal cell car-
cinoma, its role is less well defined.
Sunitinib, which is currently used as first-line treatment
in patients with metastatic renal cell carcinoma in Nor-
way, resulted in median progression-free survival of 10.8
months in a large trial where 375 patients received the
drug [15]. Its role in patients with limited performance
status and/or central nervous system metastases is not
well defined and requires additional studies. We are not
aware of clinical data supporting its use in patients with
NM. The patient presented here developed both hemato-
logic and infectious complications after 2 weeks on suni-
tinib and treatment was then discontinued. In addition,
the patient's general condition deteriorated slowly. Even-
tually, he died from pneumonia. Survival after NM was 4
months. This figure is comparable to data in mixed
patient groups (breast cancer, lymphoma, lung cancer
etc.), where those with KPS 70 or greater had median sur-
vival of 15.5 weeks and those with KPS <70 only 6 weeks
[16]. The presence or absence of CSF cytology did not
influence survival [17]. Overall, NM is often associated
with extensive extracranial disease burden and short sur-
vival in spite of treatment with radio- and chemotherapy
[18]. Performance status and extent of disease should
guide the choice of treatment [19]. Studying the role of
renal cell carcinoma-specific systemic treatment
approaches requires collaborative efforts because NM is a
rare event is this particular disease.
Figure 3 Magnetic resonance imaging (T1-weighted post Gado-
linium) showing two of several contrast-enhancing leptomenin-
geal metastases, indicated by white arrows.
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